$VRTX

AbCellera (ABCL) and Vertex (VRTX) announced a strategic collaboration to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery using its TCE platform and receive $28M upfront plus milestones and tiered royalties, while Vertex funds R&D and retains commercialization rights. The article also cites Vertex Q2 2026 revenue of $3.33B and net income of $1.1B, and AbCellera Q2 2026 revenue of $4.1M with a $55.4M net loss.

Vertex Pharmaceuticals (VRTX) reached a new all-time high, after a volatile period. In Q2, sales rose 12% to $3.33B and EPS was $4.31. CF revenue was $3.2B. Vertex expects $500M non-CF revenue in 2026, has Casgevy label expansion, and is pursuing povetacicept phase 3 with potential approval by end-November. It plans to buy Crinetics for about $10B.

Crinetics Pharmaceuticals (CRNX) said its proposed merger with Vertex Pharmaceuticals (VRTX) has progressed after Hart-Scott-Rodino waiting periods expired and antitrust approvals were received in Austria, Germany, and Australia. The deal would make Crinetics a wholly owned Vertex subsidiary, pending other conditions and CRNX shareholder approval on Aug. 28, 2026. Shares trade near $84.44.

Crinetics Pharmaceuticals said it received HSR clearance for its pending merger with Vertex, with closing expected in early September 2026, subject to shareholder approval. The HSR waiting period expired Aug. 12, 2026, and antitrust approvals were obtained in Austria, Germany and Australia, where the waiting period ends Aug. 27. A special meeting is set for Aug. 28.

RBC says Vertex Pharmaceuticals has multiple portfolio catalysts with favorable risk-reward. Separately, Jefferies raised its Vertex price target to $633 from $610 and kept a Buy rating, according to the respective firms. Vertex shares were $524.63 at 11:03am, down 0.95% on the day and up 8.38% YTD.

Analysts issued new ratings for GE Healthcare Technologies (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO). Bank of America kept GEHC at Hold with a $74 target; consensus is Moderate Buy at $79.07. Truist reiterated Buy on VRTX with consensus Strong Buy at $562.19. Truist reiterated Buy on AGIO; consensus Moderate Buy targets $41.33.

Sionna Therapeutics (NASDAQ:SION) shares fell over 90% after its Phase 2a PreciSION CF trial of SION-719 as an add-on to Vertex’s Trikafta failed its main activity endpoint, so Sionna said it will not proceed SION-719. Vertex (NASDAQ:VRTX) rose to new highs as the CF competitive overhang eased. Sionna will prioritize SION-451; Vertex cited prior strength and guidance.

Vertex Pharmaceuticals reported Q2 2026 revenue of $3,333.9 million and net income of $1,099.8 million, and raised full-year 2026 total revenue guidance to $13.1 billion to $13.2 billion. It also partnered with AbCellera to develop multispecific T-cell engagers. The article discusses implications for Vertex’s CF outlook and longer-term growth targets.

Vertex (VRTX) reported Q2 2026 revenue of $3,333.9 million, up 12% year over year, and raised full-year 2026 guidance to $13.1 billion to $13.2 billion. Cystic fibrosis revenue was $3,207.9 million, with ALYFTREK at $573.6 million. Non-GAAP EPS was $4.73 and cash was $13.6 billion. Management also discussed the planned $8.8 billion Crinetics acquisition and a Nov. 30, 2026 PDUFA date for povetacicept.

Vertex Pharmaceuticals shares rose about 7% to around $532 after Sionna Therapeutics reported Phase 2a results for SION-719 with only a 1 mmol/L placebo-adjusted sweat chloride reduction and stopped that program. The article cites Vertex Q2 revenue of $3.33B (+12% YoY), non-GAAP EPS $4.73 (+5%), and raised 2026 revenue guidance to $13.1B-$13.2B.